Vascular access and

medication delivery

COVID-19 response efforts

Background Image
Overview
quote-icon
Emerging stronger, together

For the healthcare community. For patients. For all.

We are all working together toward one goal in health while navigating the uncertainty of COVID-19. Rest assured that BD is committed to helping you determine the best solutions across the continuum of care now and in the future as needs surrounding the pandemic continue to evolve.

The Impact of COVID-19 on Healthcare
  • The average hospital length of stay (LOS) in the U.S. is 5.5 days1, while the median LOS of COVID-19 survivors is 10 to 13 days2

    The average hospital length of stay (LOS) in the U.S. is 5.5 days1, while the median LOS of COVID-19 survivors is 10 to 13 days2

  • Almost 15% of patients hospitalized with COVID-19 required renal replacement therapy (RRT)3

  • The U.S. government has purchased sufficient COVID-19 vaccine doses to vaccinate 300 million people4

    The U.S. government has purchased sufficient COVID-19 vaccine doses to vaccinate 300 million people4

KEY CHALLENGES

Treating COVID-19 Patients is Complex—We can Help

Key challenges your facility may be facing

COVID-19 vaccination preparedness

As COVID-19 vaccinations accelerate and researchers continue pursuing novel vaccines and treatments, BD is responding with a full suite of medication delivery devices to meet the needs of each potential drug. We are continuing to work with the U.S. government to understand needs, scaling up production and ensuring supply availability for safe administration of vaccines.

Learn More

Selecting the most appropriate device to extend dwell time and reduce catheter restarts

  • BD Nexiva™ Closed IV Catheter System

    Shown to preserve sites for longer and is designed to protect patients by reducing the risk of complications and restarts*5,6

    Learn More

    forward-arrow
  • PowerGlide Pro™ RT Midline Catheter

    Provides power injection and blood draw capability, indicated for up to 29 days dwell-time for longer-term therapy

    Learn More

    forward-arrow
  • PowerPICC™ Provena™ Catheter

    Provides reliable vascular access with multiple lumen options and smaller diameters*** for short and long term infusion therapy.

    Learn More

    forward-arrow
  • Power-Trialysis™ Short-Term Triple Lumen Dialysis Catheter

    Offers kink resistance and a third power-injectable lumen for multiple therapies for patients in need of dialysis

    Learn More

    forward-arrow

Helping to reduce complications

  • BD ChloraPrep™ Patient Preoperative Skin Preparation with Sterile Solution™

    An FDA-approved dual antiseptic of 2% CHG† and 70% IPA‡ that kills bacteria more effectively than single agents, providing both immediate and persistent activity 7,8

    Learn More

    forward-arrow
  • BD Nexiva™ Closed IV Catheter System

    An integrated extension tubing and stabilization platform reduces the risk of dislodgment and related complications §5,6

    Learn More

    forward-arrow
  • BD Max needle-free connector technology includes the BD MaxPlus™ Needle-Free Connector

    The only needle-free connector proven to reduce CLABSIs.

    Learn More

    forward-arrow
  • Tip Confirmation Systems (TCS) including the Sherlock 3CG+™ TCS

    Eliminates the need for chest X-rays and helps the clinician clear the line, enabling immediate therapy use# **††

     

    Learn More

    forward-arrow
  • Max Barrier + PICC Trays

    Align with recommendations from The Joint Commission and the Infusion Nurses Society (INS) to use a cart or kit that contains all necessary supplies 9,10

    Learn More

    forward-arrow
  • BD Vascular Access Management Program

    An integrated approach for vascular access device selection, placement, and care designed to help reduce vascular access related complications, which may lead to improved patient care.

    Learn More

    forward-arrow

Minimizing patient and clinician exposure

  • BD Nexiva™ Closed IV Catheter System

    Shown to preserve sites for longer and designed to protect patients by reducing the risk of complications and restarts 5,6

    Learn More

    forward-arrow
  • BD Ultrasound Probe Covers

    Sheathes the ultrasound probe, helping to reduce the level of contamination and the risk of infection

    Learn More

    forward-arrow
  • BD PhaSeal™ Optima System

    A closed-system drug transfer device (CSTD) designed with no inlets or air exchange for completely airtight hazardous drug transfers

    Learn More

    forward-arrow

Manufacturing and logistics have been amplified to ensure continuous product availability

We are:

  • Mobilizing manufacturing workforce to maintain production and availability of products.
  • Increasing production of critical supplies and ongoing investments in global manufacturing capacities to strengthen inventory
  • Closely monitoring inventory and customer ordering, and placing critical products on manual inventory allocation, to ensure supply continuity


Learn More

Staff Training and Education Gaps
Advantages of the BD Nexiva™ Closed IV Catheter System
Infographic
Advantages of the BD Nexiva™ Closed IV Catheter System

The COVID-19 pandemic has heightened clinicians’ awareness of the potential risks of exposure to bloodborne pathogens when starting and managing peripheral IV catheters (PIVCs).

 

Download

Notes

* Compared to an open system

† Chlorhexidine gluconate

‡ Isopropyl alcohol

§ Compared to B. Braun Introcan Safety® Catheter with Bard Statlock® IV Ultra Stabilization Device

‖ The BD Max needle-free connector technology includes the BD MaxPlus™ Needle-free Connector and the BD MaxZero™ Needle-free Connector.

¶ For CVAD tip placement confirmation of approaches from the superior vena cava.

# When compared to traditional PICC placement methods of blind placement and chest X-ray (CXR).

** Company sponsored study comparing Sherlock 3CGTM TCS on adult patients against historical PICC placement standard of care for blind insertion by a CXR for tip confirmation. Data on file.

†† Reduced cost based on post-hoc exploratory analysis suggesting the costs between the two placement processes are different.

*** Comparison in relation to Bard PowerPICC™ Catheters

Reference
  1. Length of hospital stay (indicator). Organisation for Economic Cooperation and Development (OECD) iLibrary website. https://www.oecd-ilibrary.org/social-issues-migration-health/length-of-hospital-stay/indicator/english_8dda6b7a-en. Published 2019. Accessed July 27, 2020.
  2. Interim Clinical Guidance f¬or Management of Patients with Confirmed Coronavirus Disease (COVID-19). Centers for Disease Control and Prevention (CDC) website. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Published 2020. Updated June 30, 2020. Accessed July 15, 2020.
  3. Acute kidney injury in patients hospitalized with COVID-19. Hirsch, Jamie S.Abate, Mersema et al. Kidney International, Volume 98, Issue 1, 209 - 218.
  4. Biden Administration purchases additional doses of COVID-19 vaccines from Pfizer and Moderna. February 2021. https://www.hhs.gov/about/news/2021/02/11/biden-administration-purchases-additional-doses-covid-19-vaccines-from-pfizer-and-moderna.html [online] Available at [Accessed 03 May 2021]. Accessed March 3, 2021.
  5. González López JL, Vilela AA, Fernández del Palacio E, Corral JO, Martí CB, Portal PH. Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. J Hosp Infect. 2014;86(2):117–126. doi:10.1016/j.jhin.2013.10.008.
  6. Bausone-Gazda D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheter stabilization systems. J Infus Nurs. 2010;33(6):371–384. doi:10.1097/NAN.0b013e3181f85be2.
  7. Ostrander RV, Botte MJ, Brage ME. Efficacy of surgical preparation solutions in foot and ankle surgery. J Bone Joint Surg Am. 2005;87(5):980–5. doi: 10.2106/JBJS.D.01977.
  8. Saltzman MD, Nuber GW, Gryzlo SM, Marecek GS, Koh JL. Efficacy of surgical preparation solutions in shoulder surgery. J Bone Joint Surg Am. 2009;91(8):1949–53. doi: 10.2106/JBJS.H.00768
  9. Infusion Nurses Society. Infusion Therapy Standards of Practice. J Infus Nurs. 2021;44(1S):S1–224.
  10. The Joint Commission. Preventing Central Line–Associated Bloodstream Infections: A Global Challenge, a Global Perspective. Oak Brook, IL: Joint Commission Resources, May 2012.

Let’s talk about how to support your COVID-19 efforts

Receive emails about the latest BD webinars, trade shows, training opportunities and other invitation-only events

Subscription Form

BD-23877 (05/21)

Chat with us
Our live chat is available between the hours of 8.30am - 5.00pm EST, Monday - Friday
×
Chat with us
Our live chat is available between the hours of 8.30am - 5.00pm EST, Monday - Friday
×